In 2019, the Food and Drug Administration (FDA) approved Evenity (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal people.
Evenity is intended for people who have a high risk of fracture or a history of fracture, or who haven't responded well to other osteoporosis treatments.